| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | 706.45% | HC Wainwright & Co. | $80 → $75 | Maintains | Buy |
| 08/17/2023 | 760.22% | HC Wainwright & Co. | $80 → $80 | Reiterates | Buy → Buy |
| 08/17/2023 | 179.57% | Chardan Capital | → $26 | Reiterates | Buy → Buy |
| 07/24/2023 | 115.05% | Morgan Stanley | $20 → $20 | Reiterates | Overweight → Overweight |
| 07/17/2023 | 115.05% | Morgan Stanley | $20 → $20 | Reiterates | Overweight → Overweight |
| 06/26/2023 | 115.05% | Morgan Stanley | $20 → $20 | Reiterates | Overweight → Overweight |
| 06/20/2023 | 115.05% | Morgan Stanley | → $20 | Reiterates | → Overweight |
| 06/12/2023 | 115.05% | Morgan Stanley | → $20 | Reiterates | → Overweight |
| 05/18/2023 | 760.22% | HC Wainwright & Co. | → $80 | Reiterates | Buy → Buy |
| 05/11/2023 | 760.22% | HC Wainwright & Co. | → $80 | Reiterates | Buy → Buy |
| 05/08/2023 | 115.05% | Morgan Stanley | → $20 | Initiates Coverage On | → Overweight |
| 03/17/2023 | 760.22% | HC Wainwright & Co. | → $80 | Reiterates | → Buy |
| 03/16/2023 | 179.57% | Chardan Capital | $29 → $26 | Maintains | Buy |
| 12/09/2022 | 93.55% | Morgan Stanley | → $18 | Initiates Coverage On | → Equal-Weight |
| 12/06/2022 | 760.22% | HC Wainwright & Co. | $95 → $80 | Maintains | Buy |
| 11/17/2022 | 211.83% | Chardan Capital | $33 → $29 | Maintains | Buy |
| 03/31/2022 | 254.84% | Chardan Capital | → $33 | Initiates Coverage On | → Buy |
| 03/22/2022 | 921.51% | HC Wainwright & Co. | $100 → $95 | Maintains | Buy |
What is the target price for Silence Therapeutics (SLN)?
The latest price target for Silence Therapeutics (NASDAQ: SLN) was reported by HC Wainwright & Co. on November 17, 2023. The analyst firm set a price target for $75.00 expecting SLN to rise to within 12 months (a possible 706.45% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Silence Therapeutics (SLN)?
The latest analyst rating for Silence Therapeutics (NASDAQ: SLN) was provided by HC Wainwright & Co., and Silence Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Silence Therapeutics (SLN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Silence Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Silence Therapeutics was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
Is the Analyst Rating Silence Therapeutics (SLN) correct?
While ratings are subjective and will change, the latest Silence Therapeutics (SLN) rating was a maintained with a price target of $80.00 to $75.00. The current price Silence Therapeutics (SLN) is trading at is $9.30, which is out of the analyst's predicted range.